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Dietary nitrate in decreased blood
pressure in obstructive sleep apnoea
syndrome: a series of N-of-1trials
Conor P. Kerleya,b, Liam CormicanAQ1
a, and
Eamon Dolanc
Obstructive sleep apnoea syndrome (OSAS) is aconsequence of repetitive oropharyngeal airwaynarrowing/closure during sleep resulting in
chronic intermittent hypoxaemia [1]. OSAS is regarded as
an independent risk factor for hypertension (HTN) devel-
opment [2] and is associated with decreased cerebral blood
flow [3], leading to daytime neuropsychological sequelae
[1]. Blood pressure (BP) follows a circadian rhythm termed
dipping and the absence of nocturnal BP dipping is associ-
ated with target-organ damage, cerebrovascular disease,
myocardial remodelling and increased cardiovascular
events/mortality [4]. Abnormal BP in OSAS typically mani-
fests as reduced nocturnal BP dipping [5]. Although con-
tinuous positive airway pressure therapy (CPAP) represents
the current gold standard treatment of OSAS, its antihyper-
tensive effect isAQ4 limited [6].
Nitrate/nitrite levels indicate the bioavailability of nitric
oxide (NO) [7], which is a potent vasodilator. Decreased
serum nitrate/nitrite has been reported in OSAS compared
with controls [8–10], which could play a significant role in
the vascular/neuropsychological consequences of OSAS.
Supplementation with dietary nitrate, through reduction to
nitrite, has emerged as a novel strategy to increase NO
bioavailability and decreased BP in a number of popu-
lations [11–13]. We have recently shown an acute BP
decrease in the hypoxic condition of COPDAQ5 after nitrate
compared with placebo [12]. Further, a previous fMRI study
demonstrated an acute increase in brain perfusion follow-
ing dietary nitrate consumption [14].
The nitrate pathway is upregulated under hypoxic con-
ditions [15]. As OSAS is associated with, neuropsychological
consequences and elevated BP, dietary manipulation could
represent a novel adjunctive method of treatment of OSAS
associated with cardiovascular risk. Evidence regarding
specific nutritional intervention in OSAS is lacking. We
wanted to assess the effects of dietary nitrate in a prelimi-
nary but reliablemanner using a series of n-of-1 trials before
embarking on a more rigorous, double-blind, placebo-
controlled trial.
We recruited three middle-aged (mean age¼ 53 years),
obese (mean BMI¼ 38 kg/m2), Caucasian, CPAP naı¨ve
males with severe OSAS (mean AHI¼ 34) from the sleep
clinics of Connolly Hospital (Dublin, Ireland) (Table 1). We
excluded study participants who were clinically unstable or
using CPAP, organic nitrates or antibiotics. However, two of
the study participants were on antihypetensives and two of
the study participants were on antidiabetic medications.
This study was approved by the Human Research Ethics
Committee of Connolly Hospital, Dublin and written
informed consent was obtained from all study participants.
During this randomized, controlled, single-blind, cross-
over, study participants were tested on three occasions, 14
days apart. On the morning of testing, study participants
consumed an identical, light, self-selected breakfast and
refrained from alcohol and tobacco. On test days, in an
identical manner at the same time of day, study participants
had blood drawn for nitrate analysis with the widely used
and validated Sievers Nitric Oxide Analyzer [12] and com-
pleted the following validated questionnaires: Epworth
Sleepiness scale, Pittsburgh Sleep Quality Index, Fatigue
Severity Scale and Beck Depression Inventory as well as
completing trail making forms A and B, which assess visual
attention and task switching by timing the participants
speed of completion [16]. After these assessments, study
participants wore the noninvasive ambulatory blood
monitor (ABPM) Spacelabs 90207 device (Spacelabs
Healthcare Ltd., Issaquah, Washington, USA) for 24 h,
which has previously been validated by the British Hyper-
tension Society.
Following completion of baseline assessments, the three
study participants were randomized to drink either 140ml
concentrated, nitrate-rich beetroot juice (BRJ) (12.9mmol
nitrate) or 140ml water (<0.5mmol nitrate) 1 h prior to
bedtime for 14 days followed by the crossover condition.
The standardized dose of nitrate is attainable with a diet rich
in vegetables [17]. We did not include a washout period
since the half-life of dietary nitrate is "6 h and the bio-
activity of nitrate returns to baseline 24 h after a bolus dose
[18]. Instructions not to alter dietary, tobacco, alcohol,
exercise and medication habits were provided to all study
participants and advice to avoid use of mouthwash, which
is known to decrease nitrite and NO formation from dietary
nitrate [19].
For this series of N-of-1 trials, we did not perform a
sample size calculation, rather we were interested in the
acceptability of our trial design and to assess if dietary
nitrate had any effect on BP profiles and several secondary
measures. Data was normally distributed and we used 1-
tailed, paired t-tests as recommended for use in N-of-1 trials
[20] to compare the changes after BRJ to the changes after
water. We selected nocturnal SBP as the primary outcome
because existing literature suggests dietary nitrate has
hypotensive effects [11–13] and OSAS is associated with
HTN [2,5], which is difficult to treat [6].
The three study participants completed all measures and
had 100% compliance with the beverages and reported no
lifestyle of medical changes during the protocol. Table 1
displays results for measures of sleep, fatigue, mood, neu-
ropsychological function, BP and serum nitrate. Further,
there was a significant negative correlation between serum
nitrate and nocturnal SBP values from pooled analysis from
the study participants at the 3 time-points (r¼#0.6;
P¼ 0.043).
OSAS is highly prevalent and independently associated
with elevated BP [2]. OSAS related HTN is predominantly
nocturnal, manifesting as lack of nocturnal BP dipping [5]
Journal of Hypertension www.jhypertension.com 1
Correspondence
CE: Namrta; JH-D-15-01080; Total nos of Pages: 4;
JH-D-15-01080
and is difficult to treat. CPAP represents the gold standard
treatment for OSAS but according to a recent, comprehen-
sive meta-analysis, the antihypertensive effect size is small
(2.6 and 2mmHg drop in SBP and DBP, respectively) [6].
To our knowledge, this is the first report of dietary
nitrate in OSAS study participants. In this single-blind,
crossover study of CPAP naı¨ve, severe, OSAS study partici-
pants, we demonstrate that 14 days of nocturnal BRJ
significantly increased serum nitrate (P¼ 0.024) and
improved symptomatology, particularly fatigue as well
as visual attention (P¼ 0.018 and 0.02, respectively). We
noted improvements in BP profiles including a nocturnal
BP decrease with BRJ consumption (#12/#4mmHg) com-
pared to water control (þ5/þ3mmHg) (Table 1).
Although, there was no statistical difference in our primary
end point (nocturnal SBP), the size of the effect was
clinically significant. For example, it has been estimated
that a SBP reduction of 5mmHg could decrease the risk of
mortality because of stroke and CVD by 14 and 9% and 14%
[13]. Our findings support previous findings of decreased
BP in healthy volunteers [11], study participantswith COPD
[12] and hypertensive study participants [21] following
nitrate consumption. The BP lowering effect we observed
(#12/#4mmHg) was greater than that previously
observed in clinical populations with ABPM, including
among hypertensives (#7.7/#5.2mmHg). It is possible
that dietary nitrate will have a greater hypotensive role
in hypoxic conditions, such as OSAS, because of upregu-
lated reduction of nitrate to NO [15]. Additionally, we
observed a significant, inverse correlation between pooled
serum nitrate values and nocturnal SBP values. Previously,
negative correlations have been demonstrated between
nitrate levels and OSAS severity [8–10] as well as SBP
in OSAS [8], raising the intriguing possibility that the
pathogenesis of HTN in OSAS may be related to the NO
bioavailability, and that NO manipulation may have thera-
peutic potential.
Our pilot study is important for several reasons. It is the
first report of dietary nitrate provision in OSAS – a common
syndrome associated with neuropsychological sequelae
and difficult to treat HTN. The study participants were
phenotypically similar (male, severe OSAS and Caucasian)
and typical of the OSAS population attending sleep medi-
cine clinics (obese, sedentary, comorbidities present).
Interestingly, a recent trial demonstrated a lack of benefit
of dietary nitrate in type 2 diabetes [22]. The large BP
reductions observed here may because of hypoxic upre-
gulation of the nitrate-NO pathway [5]. Two of the three
study participants were on antihypertensive medications
and baseline ABPM values revealed well controlled SBP in
all 3 study participants (122, 122 and 125mmHg respect-
ively). Nevertheless, nocturnal BRJ supplementation was
associated with decreased 24 h and particularly nocturnal
BP as well as increased SBP and DBP dipping.
We included stable OSAS outpatients with no medical
changes throughout the study. Further, nitrate has a short
half-life ("6 h) [18] and rapidly measurable biochemical/
physiological effects. These characteristics are essential for
n-of-1 trials [23,24]. Although we included homogenous
study participants in whommedication and CPAP exposure
did not change, our pilot study is limited by a small sample
size and the lack of a true placebo. However, values for all
parameters were similar at baseline and after water control
suggesting that the dietary nitrate was responsible for the
effects. Our preliminary findings suggest a potential benefit
of dietary nitrate in OSAS, at least in Caucasian males with
severe OSAS.
Nocturnal CPAP represents the current gold standard
treatment of OSAS. However, the antihypertensive effect
size is small [6]. Although the lack of effect may be because
of noncompliance, there are few therapeutic alternatives to
CPAP and scope exists for the development of adjunctive
therapeutic modalities directed towards the attenuation of
the hypertensive burden of OSAS.
Nocturnal dietary nitrate may improve NO bioavailability
in OSAS, resulting in direct benefits to BP profiles, particu-
larly nocturnal BP. Further work with a larger sample and a
true placebo is required to evaluate this therapeutic con-
cept. Our group are currently conducting a double-blind,
placebo-controlled crossover trial among OSAS study
participants to determine the effect, if any, of dietary nitrate
in OSAS.
TABLE 1. Mean values for baseline post-beetroot juice and post-water assessments
Baseline AQ6BRJ
% Water% P value
ESS (0–24) 13 5 (#8) 11 (#2) 0.1
PSQI (0–21) 6 4 (#2) 6 (0) 0.1
FSS (0–60) 45 28 (#17) 38 (#7) 0.018
BDI (0–63) 13 3 (#10) 10 (#3) 0.13
Trail making A (s) 30 27 (#3) 34 (þ4) 0.02
Trail making B (s) 51 40 (#11) 61 (þ10) 0.056
Mean 24-h SBP (mmHg) 117 114 (#3) 125 (þ12) 0.12
Mean 24-h DBP (mmHg) 73 73 (0) 76 (þ3) 0.24
Mean nocturnal SBP (mmHg) 118 106 (#12) 123 (þ5) 0.08
Mean nocturnal DBP (mmHg) 71 67 (#4) 74 (þ3) 0.1
% nocturnal SBP readings above limits 41.8 11.1 56.9 0.08
% nocturnal DBP readings above limits 62.9 42.3 49.7 0.12
% dipping SBP #1.3 7.5 (þ8.8) 2.7 (þ4) 0.09
% dipping DBP 4.3 10.4 (þ6.1) 4.3 (0) 0.07
NO3
# (mmol/l) AQ740 181 (þ141) 43 (þ3) 0.024
BDI, Beck Depression Inventory; ESS, Epworth Sleepiness scale; FSS, Fatigue Severity Scale; NO3
#, serum nitrate; PSQI, Pittsburgh Sleep Quality Index.
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